Sydney, NSW: Australian biotechnology firm Next Science today announced that it had entered into an exclusive, worldwide distribution agreement with US-based diversified manufacturer 3M Company for the sales and marketing of Next Science’s BlastX™ Antimicrobial Wound Gel. Read the Full Release
Sydney, NSW and Jacksonville, FL: Next Science® is excited to announce the release of its newest product, SurgX™, available in the US market. SurgX™ is an innovative and first of its type, sterile antimicrobial surgical wound gel designed to help reduce superficial surgical site infections (SSIs) through the management and protection of the post-surgical wound … Read More
Sydney, NSW: Next Science is excited to announce the appointment of Aileen Stockburger and Mark Compton (AM) to the Board of the company as Non-Executive Directors. Both bring a wealth of diverse international healthcare experience to the Board, as the company expands the adoption of its Xbio™ Technology and the product applications globally across wound … Read More
Next Science welcomes George Savvides to its board of directors as Independent Chairperson. Mr Savvides is currently on the board of directors of Ryman Healthcare. He serves as the Chairman of both Macquarie University Hospital and Kings Transport Group Ltd, and is the Deputy Chairman of the Australian public broadcaster, SBS. Read the Full Release
Next Science is excited to announce it is hosting an advanced education forum explaining the state-of-the-art technology of its BlastX Antimicrobial Wound Gel on Saturday, April 28, 2018. The event is part of SAWC Spring, the Symposium on Advanced Wound Care. Read the Full Release
Next Science is excited to announce the results of a prospective, randomized 12-week Mayo Clinic study about the use of BlastX antimicrobial wound gel on chronic wounds to determine if disrupting chronic wound biofilm is therapeutically efficacious. The positive results are published in WOUNDS®. The study represents statistically significant findings for both reduction in wound … Read More
Next Science is pleased to announce the publication of a comprehensive article about the application of its Xbio technology to help prevent the development of E. coli biofilms on urinary tract catheters, a leading cause in catheter-associated urinary tract infections. The results are published in the Journal of Medical Microbiology & Diagnosis. View Publication Read … Read More
Next Science is proud to announce that Judith Mitchell has been appointed to its board of directors as Director and Chief Executive Officer. Ms. Mitchell joined Next Science in August 2017. Most recently she was President, DePuy Synthes Asia Pacific, the Orthopaedics Division of Johnson & Johnson.
Next Science will highlight its BlastX Antimicrobial Wound Gel at three upcoming conferences. It will exhibit at the Wild on Wounds National Wound Conference in Las Vegas, Nevada, from October 4-7. In addition to exhibiting, it will make poster presentations at SAWC Fall from October 19-22, also in Las Vegas. And Next Science will exhibit … Read More
Next Science’s proprietary BlastX Antimicrobial Wound Gel is highlighted in a recently published consensus paper on biofilm disruption and treatments. The novel Xbio™ technology in BlastX inhibits biofilm development by gram-positive and gram-negative wound pathogens.